DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment

Information source: Shinshu University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: Ibandronic acid, vitamin D (Device)

Phase: Phase 4

Status: Recruiting

Sponsored by: Shinshu University

Overall contact:
Yukio Nakamura, MD, PhD, Phone: +81-263-37-2659, Email: yxn14@aol.jp

Summary

To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients

Clinical Details

Official title: Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Changes of bone mineral density

Secondary outcome: Improvement of bone turnover markers

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Osteoporosis

Exclusion Criteria:

- Kidney, parathyroid, congenital bone metabolic disease

Locations and Contacts

Yukio Nakamura, MD, PhD, Phone: +81-263-37-2659, Email: yxn14@aol.jp

Showa Inan General Hospital, Komagane, Nagano 399-4117, Japan; Recruiting
Yukio Nakamura, MD, PhD, Phone: +81-263-37-2659, Email: yxn14@aol.jp
Additional Information

Starting date: June 2014
Last updated: May 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017